Delavirdine: A review of its use in HIV infection

Drugs

Volumn 60, Issue 6, 2000, Pages 1411-1444

  Scott, Lesley J ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CARBAMAZEPINE; DELAVIRDINE; DIDANOSINE; ERGOT DERIVATIVE; LAMIVUDINE; MEVINOLIN; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; PLACEBO; PROTEINASE INHIBITOR; QUINIDINE; RIFABUTIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SILDENAFIL; SIMVASTATIN; UNCLASSIFIED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; LYMPHOCYTE COUNT; METABOLIC DISORDER; NONHUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; STEVENS JOHNSON SYNDROME; VIRUS LOAD;

ANTI-HIV AGENTS; DELAVIRDINE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MOLECULAR STRUCTURE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0034527006     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060060-00013     Document Type: Review

References (117)

1. The AIDS epidemic: Considerations for the 21st century
2. Overview of HIV infection
3. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA Panel
4. Triple nucleoside analogue antiretroviral therapy: Expanding the treatment approaches for management of HIV infection
5. HIV disease treatment in the era of HAART
6. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
7. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
8. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
9. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors
10. Locations of Anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance
11. Crystal structure at 3.5Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor
12. Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E
13. Characterisation of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reversetranscriptase
14. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site
15. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor
16. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immuno-deficiency vires type 1 reverse transcriptase
17. Structure of HIV-1 RT/TIBO R86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors
18. Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays
19. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication
20. In vitro inhibition of human immuno-deficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-α
21. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV
22. Anti-human immunodeficiency virus type 1 activities of U-90152 and U-75875 in human brain cell cultures
23. Inhibition of human immunodeficiency virus type I infection in vitro by combination of delavirdine, zidovudine and didanosine
24. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3-azido-3-deoxythymidine or 2,3-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro
25. Synergistic inhibition of human immuno-deficiency virus type 1 replication in vitro by two- and threedrug combinations of delavirdine, lamivudine and zidovudine
26. Interferon alpha in the treatment of AIDS-related Kaposi's sarcoma
27. The role of α-interferon in patients with human immunodeficiency virus infection
28. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
29. HIV-1 chemotherapy and drug resistance
30. Antiretroviral drug resistance testing in adult HIV-1 infection, recommendations of an International AIDS Society - USA Panel
31. The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: Biological relevance: A review
32. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs
33. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance
34. Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase
35. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
36. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors
37. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5-end- and DNA 3-end-directed RNase H activities
38. Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase
39. Relationships between delavirdine (DLV) plasma levels, HIV RNA responses and DLV resistance during combination therapy with zidovudine, and didanosine
40. 1999 Physicians GenRx. Delavirdine mesylate
41. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection
42. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test
43. Development of a nonlinear population pharmacokinetic model for delavirdine mesylate in HIV-1 patients
44. Reduced delavirdine exposure in HIV+ subjects with gastric hypoacidity
45. Plasma protein binding of delavirdine in HIV-infected patients in ACTG 260
46. Effect of food on the steady-state pharmacokinetics of delavirdine mesylate in HIV+ patients
47. Simulations with a population pharmacokinetic model for delavirdine predict the same systemic steadystate exposure for 600mg BID and 400mg TID regimens
48. Efficacy and safety of combination therapy with delavirdine and zidovudine: A European/Australian phase II trial
49. Population pharmacokinetics of delavirdine and its major metabolite, N-desalkyl delavirdine
50. Single-dose pharmacokinetic studies with delavirdine mesylate: Dose proportionality and effects of food and antacid
51. Simple, rapid and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma
52. Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fuorescence detection
53. Alterations in gastric acidity in patients infected with human immunodeficiency virus
54. In vitro protein-binding characteristics of delavirdine and its N-dealkylated metabolite
55. Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients
56. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: Probable involvement of CYP2D6 and CYP3A
57. Microsomal metabolism of delavirdine: Evidence for mechanism-based inactivation of human cytochrome P450 3A
58. Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeys
59. Metabolism of the HIV-1 reverse transcriptase inhibitor delavirdine in mice
60. Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats
61. Delavirdine mesylate
62. Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected
63. Delavirdine significantly increases plasma concentrations of amprenavir in healthy volunteers
64. Pharmacokinetic drugdrug interaction study of delavirdine and indinavir in healthy volunteers
65. The pharmacokinetics (PK) and tolerability of indinavir (IDV) and delavirdine (DLV) administered in the absence and presence of food in healthy volunteers
66. Delavirdine (DLV) and nelfinavir (NFV): A pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers
67. Delavirdine mesylate pharmacokinetics during combination therapy with ritonavir
68. Ritonavir (RIT) pharmacokinetics (PK) during combination therapy with delavirdine (DLV)
69. Pilot study of BID and TID combination of saquinavir-SGC (S), delavirdine (D), zidovudine (ZDV) and lamivudine (3TC) as initial therapy: Pharmacokinetic (PK) interaction between S-SGC and D
70. Delavirdine (D)and marketed protease inhibitors (PIs): Pharmacokinetic (PK) interaction studies in healthy volunteers
71. Evaluation of the steady-state pharmacokinetic interaction between didanosine and delavirdine mesylate in HIV+ patients
72. Zidovudine pharmacokinetics during an escalating, multiple-dose study of delavirdine mesylate
73. Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients
74. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients
75. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate
76. Drug interactions of HIV protease inhibitors
77. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy
78. Predictors of optimal virological response to potent antiretroviral therapy
79. Twice daily dosing of delavirdine in combination with nelfinavir, didanosine, and stavudine results in significant decreases in viral burden
80. Phase I evaluation of delavirdine in HIV-1-infected pediatric patients
81. ACTG 260: A randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy
82. 3 (ACTG 261)
83. Final 54-week analysis of a placebo-controlled trial (13C) of delavirdine plus two nucleoside analogs (NA) versus two NA in drug-naive and -experienced indivduals
84. Safety and efficacy of delavirdine in combination with zidovudine and lamivudine: Final 52-week analysis
85. Final 54-week analysis of a study comparing the safety and antiretroviral activity of dual nucleoside analogues plus delavirdine (DLV) in an advanced treatment-naive HIV-infected patients
86. Final 54-week analysis of a study comparing the safety and the antiretroviral activity of dual nucleosides analogues plus placebo versus dual nucleoside analogues plus delavirdine in an advanced, nucleoside analogue-experienced HIV-infected population
87. Randomized, openlabel comparison of saquinavir soft gel capsules (SQV), lamivudine (3TC) and delavirdine (DLV) twice or thrice daily vs SQV/3TC/zidovudine (ZDV) vs SQV/3TC/ZDV/DLV in the initial treatment of HIV infection
88. Potential antiviral activity using delavirdien and reduced-dose indinavir combination therapies
89. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: Results of Adults AIDS Clinical Trials protocol Group 370
90. Potent activity with lower doses of indinavir, using delavirdine in combination with zidovudine: 48-week analysis
91. Durable viral suppression with rescriptor (delavirdine) and indinavir combination therapies
92. A pilot study of a twice daily (BID) combination of indinavir/delavirdine plus nucleoside analogues for salvage therapy in HIV-1 infected patients
93. Salvage therapy with saquinavir SGC (SQV) in combination with ritonavir (RTV) or nelfinavir (NFV) plus delavirdine (DLV), adefovir dipivoxil (ADV), or both - ACTG 359
94. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor
95. Delavirdine in combination therapy has a favorable liver safety profile in HIV-1 patients
96. Treatment with delavirdine in combination with NRTIs and/or PIs is not associated with lipodistrophy or metabolic lipid/glucose disturbances
97. Changing patterns of mortality across Europe in patients infected with HIV-1
98. Declining morbidity and mortality among patients with advanced human immunodeficiencey virus infection
99. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality
100. Mortality impact of the AIDS epidemic: Evidence from community studies in less developed countries
101. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
102. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
103. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
104. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
105. The use of combination antiretroviral therapy in HIV-infected patients
106. When do HIV-infected persons start with antimtroviral therapy? A retrospective analysis of patients' monitoring and treatment status in general practice, as compared with the 1991 Dutch HIV treatment guidelines
107. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositiveindividuals
108. Choosing the best initial therapy for HIV-1 infection
109. Attaining higher goals in HIV treatment: The central importance of adherence
110. A risk-benefit assessment of HIV protease inhibitors
111. Human immunodeficiency virus protease inhibitors
112. Nevirapine: A review of its use in the prevention and treatment of paediatric infection